BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

Myeloproliferative Neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of JAK-STAT signaling, which responds to treatment with the JAK1 & 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary AML (sAML), where standard induction chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Saenz, Dyana T., Fiskus, Warren, Manshouri, Taghi, Rajapakshe, Kimal, Krieger, Stephanie, Sun, Baohua, Mill, Christopher P., DiNardo, Courtney, Pemmaraju, Naveen, Kadia, Tapan, Parmar, Simrit, Sharma, Sunil, Coarfa, Cristian, Qiu, Peng, Verstovsek, Srdan, Bhalla, Kapil N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345582/
https://www.ncbi.nlm.nih.gov/pubmed/27677740
http://dx.doi.org/10.1038/leu.2016.260

Ejemplares similares

Ejemplares similares